DAFTAR PUSTAKA

Barbosa, T. M., Levy, S. B. 2000. The impact of antibiotoc use on resistance development and persistence. Drug Resistance Updates (2000) 3, 303-311. 2000 Harcourt Publishers Ltd.

Fattal, M.G. 2004. *Bacterial Resistance : Changing Clinical Practice.* Servier International - 22, rue Garnier - 92200Neuilly-sur-Seine - France.

Fidler, D. P. 1998. Legal Issues associated with Antimicrobial Drug Resistance. *Emerg. Infect.* Dis.4 ; 169 - 177.

Gould, I.M. 1999. Areview of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemoter ; 43 : 459 - 465.

Gallaghar S.A, Hemphill R.R. Urinary Tract Infection : Epidemiology, Detection, and Evaluation. Dikutip dari http://www. yahoo.com.2005.

Lukasova, J. Sustackova, A. 2003. Review Article : Enterococci and Antibiotic Resistance. *Vet Brno,* 72 : 315 - 323.

Leekha, S.,et al. (2011). *General Principles of Antimicrobial Therapy,*. Mayo Clin Proc ; 86 (2) : 156 -157.

Rajabnia, M., Gooran S., Fazeli, F., Dashipour, A, (2012). Antibiotic resistance pattern in urinary tract infections in Imam-Ali hospital Zahedan 2010-2011. *Zahedan Journal of Research in Medical Science* : Zahedan.

Simon H, Cannistra S.A. Etkin M.J et al : Urinary Tract Infection, dikutip dari http://www.well-conected.com.2001.

Tenover, F.C. 2006. Mechanisms of Antimicrobial Resistance in Bacteria. *The American Journal of Medicine* Vol 119 (6A), S3 - S10.

Wagelehner FME and Neber KG dan Wagenlehner FME. Treatment of Bacterial Urinary Tract Infections : Presence and Future. European Urology 46 (2006), 235 - 244.

UNIVERSITAS PGRI ADI BUANA SURABAYA
FAKULTAS SAINS TEKNOLOGI
Badan Penyelenggara PPLP PT PGRI Surabaya

Keputusan MENKUMHAM RI NO. AHU-0000485.AH.01.08.Tahun 2019

Kampus Pusat: Jl. Dukuh Menanggal XII-4 Surabaya 60234 Telp. (031) 8281181

http://www.unipasby.ac.id

BERITA ACARA BIMBINGAN SKRIPSI

1. NAMA : Elok Trijayanti
2. NIM : 172509004
3. PRODI : Biologi
1. JUDUL : Potensi Uji Ampicillin dan Amoxicillin Terhadap Bakteri *Exterococcus Faecalis* di Kultur Urine pada Penderita Infeksi Saluran Kemih
2. TANGGAL PENGAJUAN : 9 Oktober 2019
3. PEMBIMBING : Ir. Susie Amilah., M.Si
4. PERIODE : 2019-2020
5. BERLAKU SEMESTER : Genap
6. PELAKSANAAN KONSULTASI BIMBINGAN:

NO.	TANGGAL	URAIAN KETERANGAN	PARAF
1	16 Oktober 2019	Konsultasi judul	
2	13 November 2019	BAB I dan BAB II	
3	17 Desember 2019	BAB III dan BAB IV	
4	28 Desember 2019	Kerangka Pemikiran dan Hipotesis	
5	08 Januari 2020	BAB IV Metodologi Penelitian	
6	Februari - April 2020	Penelitian	
7	14 Mei 2020	BAB V Hasil Penelitian dan Pembahasan	
8	27 Juni 2020	BAB VII Kesimpulan dan Saran	

7. TANGGAL SELESAI : 15 Agustus 2020

Mengetahui

Dekan

Dra. Diah Karunia Binawati, M.Si

Surabaya, 15 Agustus 2020

Pembimbing

Ir. Susie Amilah., M.Si

UNIVERSITAS PGRI ADI BUANA SURABAYA
FAKULTAS SAINS TEKNOLOGI
Badan Penyelenggara PPLP PT PGRI Surabaya

Keputusan MENKUMHAM RI NO. AHU-0000485.AH.01.08.Tahun 2019

Kampus Pusat: Jl. Dukuh Menanggal XII-4 Surabaya 60234 Telp. (031) 8281181

http://www.unipasby.ac.id

PERBAIKAN/REVISI UJIAN SKRIPSI

1 NAMA : Elok Trijayanti

2 NIM : 172509004

3 PRODI : Biologi

4. JUDUL : Potensi Uji Ampicillin dan Amoxicillin Terhadap Bakteri *Exterococcus Faecalis* di Kultur Urine pada Penderita Infeksi Saluran Kemih

5. PEMBIMBING : Ir. Susie Amilah., M.Si

Materi Perbaikan/ Revisi Skripsi	Tanda Tangan Dosen Penguji
1. Bab VII penambahan konsentrasi dan penambahan saran	

Surabaya, 15 Agustus 2020

Pembimbing

Ir. Susie Amilah., M.Si

LABORATORIUM KLINIK Prodia
Untuk Diagnosa Lebih Baik

Love for Quality

SURAT REKOMENDASI

025/Dipo/IX/2020

Yang bertanda tangan di bawah ini menerangkan bahwa :

Nama : Elok Trijayanti

Mahasiswa : Universitas Adhi Buana - Surabaya Jurusan Biologi

NIM : 172509004

Tema :

Potensi Uji Amphicillin & Amoxicillin terhadap bakteri **Enterococcus Faecalis** di kultur urine pada penderita infeksi saluran kemih

maka bersama ini kami memberikan izin atau rekomendasi untuk melakukan penelitian dengan judul diatas di Laboratorium Klinik Prodia - Grha Prodia Surabaya, dalam rangka menyelesaikan skripsi bagi mahasiswa

Demikian surat rekomendasi ini kami buat untuk dapat di pergunakan sebagaimana mestinya.

Surabaya, 22 September 2020

PT Prodia Widyahusada Tbk

Daniel H D Prasetyo
Branch Manager

LAMPIRAN

Lampiran 1 Statistik Uji Nomalitas

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
MicAmpicilin	80	100.0%	0	.0%	80	100.0%
SensitifitasAmpicilin	80	100.0%	0	.0%	80	100.0%
MicAmoxcilin	80	100.0%	0	.0%	80	100.0%
SensitifitasAmoxcilin	80	100.0%	0	.0%	80	100.0%

Descriptives

			Statistic	Std. Error
MicAmpicilin	Mean		9.05	1.225
	95% Confidence Interval for Mean	Lower Bound	6.61	
		Upper Bound	11.49	
	5% Trimmed Mean		8.17	
	Median		2.00	
	Variance		120.099	
	Std. Deviation		10.959	
	Minimum		2	
	Maximum		32	
	Range		30	

	Interquartile Range		6	
	Skewness		1.524	.269
	Kurtosis		.658	.532
SensitifitasAmpicillin	Mean		1.98	.111
	95% Confidence Interval for Mean	Lower Bound	1.75	
		Upper Bound	2.20	
	5% Trimmed Mean		1.97	
	Median		1.50	
	Variance		.987	
	Std. Deviation		.993	
	Minimum		1	
	Maximum		3	
	Range		2	
	Interquartile Range		2	
	Skewness		.051	.269
	Kurtosis		-2.022	.532
MicAmoxcilin	Mean		10.95	1.244
	95% Confidence Interval for Mean	Lower Bound	8.47	
		Upper Bound	13.43	
	5% Trimmed Mean		10.17	
	Median		4.00	
	Variance		123.846	
	Std. Deviation		11.129	
	Minimum		4	
	Maximum		32	
	Range		28	
	Interquartile Range		4	
	Skewness		1.353	.269
	Kurtosis		-.055	.532

SensitifitasAmoxcilin	Mean		2.05	.112
	95% Confidence Interval for Mean	Lower Bound	1.83	
		Upper Bound	2.27	
	5% Trimmed Mean		2.06	
	Median		3.00	
	Variance		1.010	
	Std. Deviation		1.005	
	Minimum		1	
	Maximum		3	
	Range		2	
	Interquartile Range		2	
	Skewness		-.102	.269
	Kurtosis		-2.041	.532

Tests of Normality

	Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
MicAmpicilin	.363	80	.000	.620	80	.000
SensitifitasAmpicilin	.337	80	.000	.652	80	.000
MicAmoxcilin	.392	80	.000	.598	80	.000
SensitifitasAmoxcilin	.353	80	.000	.636	80	.000

a. Lilliefors Significance Correction

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
MicAmpicilin	80	9.05	10.959	2	32
MicAmoxcilin	80	10.95	11.129	4	32

Ranks

		N	Mean Rank	Sum of Ranks
MicAmoxcilin - MicAmpicilin	Negative Ranks	24[a]	41.98	1007.50
	Positive Ranks	47[b]	32.95	1548.50
	Ties	9[c]		
	Total	80		

a. MicAmoxcilin < MicAmpicilin

b. MicAmoxcilin > MicAmpicilin

Ranks

		N	Mean Rank	Sum of Ranks
MicAmoxcilin - MicAmpicilin	Negative Ranks	24[a]	41.98	1007.50
	Positive Ranks	47[b]	32.95	1548.50
	Ties	9[c]		
	Total	80		

a. MicAmoxcilin < MicAmpicilin

. MicAmoxcilin = MicAmpicilin

Lampiran 2 Statistik Uji Korelasi

Test Statistics[b]

	MicAmoxcilin - MicAmpicilin
Z	-1.561[a]
Asymp. Sig. (2-tailed)	.119

a. Based on negative ranks.

b. Wilcoxon Signed Ranks Test

Descriptive Statistics

	N	Mean	Std. Deviation	Minimum	Maximum
SensitifitasAmpicilin	80	1.98	.993	1	3
SensitifitasAmoxcilin	80	2.05	1.005	1	3

Ranks

		N	Mean Rank	Sum of Ranks
SensitifitasAmoxcilin - SensitifitasAmpicilin	Negative Ranks	20[a]	21.92	438.50
	Positive Ranks	23[b]	22.07	507.50
	Ties	37[c]		
	Total	80		

a. SensitifitasAmoxcilin < SensitifitasAmpicilin

b. SensitifitasAmoxcilin > SensitifitasAmpicilin

c. SensitifitasAmoxcilin = SensitifitasAmpicilin

Test Statistics[b]

	SensitifitasAmoxcilin - SensitifitasAmpicilin
Z	-.468[a]
Asymp. Sig. (2-tailed)	.639

a. Based on negative ranks.

b. Wilcoxon Signed Ranks Test